Despite its historical leadership in global bioeconomy developments, the U.S. has recently seen its biomanufacturing capabilities lag due to rapid advancements in biotechnology and rise of the other nations’ production capabilities. This shortfall highlights the need for strong domestic biomanufacturing capacity, essential for securing supply chains for biopharmaceuticals as well as economic growth through high-tech jobs and global competitiveness. To address this, Executive Order 14081 in 2022 was signed to enhance biomanufacturing through public-private partnerships — with the Manufacturing USA network playing an important role. This article explores recent activities by the three Manufacturing USA Institutes focused on advancing biomanufacturing—BioFabUSA, NIIMBL, and BioMADE. How successful these activities are in reshoring the biomanufacturing capacity will remain key areas of focus for industry stakeholders.
Related posts:
UK’s Network Approach to Infrastructure Resilience: U.K’s Infrastructure Transitions Research Consortium (ITRC)
Burgeoning microplastics pollution prompts regulatory action to protect drinking water in California
A New Way of Thinking about Materials Management: the Oregon Story
Interview with Gay Gordon-Byrne, Executive Order of The Repair Association, on the Right to Repair Movement in the U.S., the Current Landscape, Global Initiatives, and the Uphill Challenges Ahead
